Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi") , a clinical-stage biopharmaceutical company advancing innovative ...

(Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, ...

GlucoTrack Inc. GCTK shares climbed 15.98% to $0.58 in after-hours trading on Thursday. The late trading session surge ...

Glucotrack (Nasdaq:GCTK) announced that it completed a strategic business combination with Lōkahi Therapeutics.

Glucotrack has completed its business combination with Lōkahi Therapeutics, transforming the company into a Lōkahi-controlled ...

Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for ...

Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and ...

Peer-Reviewed Studiespublished in The Journal of Diabetes Research and in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support advancement of Company’s implantable CBGM ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

GlucoTrack ( (GCTK)) has issued an announcement. On December 29, 2025, Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement of pre ...